시장보고서
상품코드
1630672

처방약 시장 규모, 점유율, 성장 분석 : 제품 유형별, 치료 영역별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)

Prescription Drugs Market Size, Share, Growth Analysis, By Product Type (Generics, Orphan), By Therapy Area (Oncology, Immunology), By Route of Administration, By End-Users, By Distribution Channel, By Region - Industry Forecast 2025-2032

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 157 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 처방약 시장 규모는 2023년에 1조 2,257억 8,000만 달러로 평가되며, 2024년 1조 3,348억 7,000만 달러에서 2032년에는 2조 6,403억 6,000만 달러로 성장하며, 예측 기간 중(2025-2032년) CAGR은 8.9%로 성장할 전망입니다.

OTC(over-the-counter) 치료는 처방약보다 약효가 약하고, 오남용시 부작용이 발생할 수 있습니다. 따라서 이러한 의약품은 의사의 처방전을 통해만 구할 수 있으며, 처방전 패드나 약국 간판에 'Rx'라고 표시되어 있는 경우가 많습니다. 전 세계 의약품 지출은 예측 기간 중 상당한 시장 성장을 촉진할 것으로 예상되며, 그 주요 이유는 특수 의약품의 비용 증가와 만성질환 및 희귀질환의 치료 증가에 기인합니다. 이러한 추세는 특히 북미에서 큰 시장 점유율을 차지하고 있는 고령화로 인해 더욱 복잡해지고 있으며, 아시아태평양은 의료를 필요로 하는 방대한 인구를 바탕으로 빠르게 성장하고 있습니다. 헬스케어 인프라 투자 강화는 시장 기회를 더욱 확대할 것으로 보입니다.

목차

서론

  • 조사의 목적
  • 조사 범위
  • 정의

조사 방법

  • 정보 조달
  • 2차 데이터와 1차 데이터 방법
  • 시장 규모 예측
  • 시장의 전제조건과 제한

개요

  • 세계 시장 전망
  • 공급과 수요의 동향 분석
  • 부문별 기회 분석

시장 역학과 전망

  • 시장 개요
  • 시장 규모
  • 시장 역학
    • 촉진요인과 기회
    • 억제요인과 과제
  • Porter의 산업 분석

주요 시장 인사이트

  • 주요 성공 요인
  • 경쟁의 정도
  • 주요 투자 기회
  • 시장 에코시스템
  • 시장의 매력 지수(2024년)
  • PESTEL 분석
  • 거시경제 지표
  • 밸류체인 분석
  • 가격 분석
  • 기술의 진보
  • 규제 상황
  • 사례 연구

처방약 시장 규모 : 제품 유형별

  • 시장 개요
  • 제네릭
  • Orphan
  • 기타 처방약

처방약 시장 규모 : 치료 영역별

  • 시장 개요
  • 종양학
  • 면역학
  • 안과
  • 호흡기
  • 피부과
  • 소화기 내과
  • 비뇨기과
  • 부인과
  • 내분비학
  • 기타

처방약 시장 규모 : 투여 경로별

  • 시장 개요
  • 경구
  • 국소
  • 비경구
  • 기타

처방약 시장 규모 : 최종사용자별

  • 시장 개요
  • 병원
  • 전문 클리닉
  • 홈케어
  • 기타

처방약 시장 규모 : 유통 채널별

  • 시장 개요
  • 병원 약국
  • 소매 약국
  • 온라인 약국
  • 기타

처방약 시장 규모

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 스페인
    • 프랑스
    • 영국
    • 이탈리아
    • 기타 유럽 지역
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 기타 라틴아메리카 지역
  • 중동 및 아프리카
    • GCC 국가
    • 남아프리카공화국
    • 기타 중동 및 아프리카

경쟁 정보

  • 상위 5사의 비교
  • 주요 기업의 시장 포지셔닝(2024년)
  • 주요 시장 기업이 채택한 전략
  • 시장의 최근 동향
  • 기업의 시장 점유율 분석(2024년)
  • 주요 기업의 기업 개요
    • 회사 개요
    • 제품 포트폴리오 분석
    • 부문별 점유율 분석
    • 매출의 전년대비 비교(2022-2024)

주요 기업 개요

  • Pfizer Inc.(United States)
  • Johnson & Johnson(United States)
  • Roche Holding AG(Switzerland)
  • Merck & Co., Inc.(United States)
  • AbbVie Inc.(United States)
  • Novartis AG(Switzerland)
  • Bristol-Myers Squibb Company(United States)
  • Sanofi S.A.(France)
  • AstraZeneca plc(United Kingdom)
  • GlaxoSmithKline plc(GSK)(United Kingdom)
  • Eli Lilly and Company(United States)
  • Gilead Sciences, Inc.(United States)
  • Amgen Inc.(United States)
  • Bayer AG(Germany)
  • Takeda Pharmaceutical Company Limited(Japan)
  • Novo Nordisk A/S(Denmark)
  • Merck KGaA(Germany)
  • Biogen Inc.(United States)
  • Teva Pharmaceutical Industries Ltd.(Israel)

결론과 권장사항

KSA 25.02.20

Global Prescription Drugs Market size was valued at USD 1225.78 billion in 2023 and is poised to grow from USD 1334.87 billion in 2024 to USD 2640.36 billion by 2032, growing at a CAGR of 8.9% during the forecast period (2025-2032).

The over-the-counter (OTC) treatments are less potent than prescription medications, leading to potential adverse effects if misused. Consequently, these medications can only be obtained through a doctor's prescription, often denoted by "Rx" on prescription pads and pharmacy signage. Global pharmaceutical spending is anticipated to drive significant market growth during the forecast period, primarily due to the increasing costs of specialized drugs and the rise in medical treatments for chronic and rare illnesses. This trend is compounded by an aging population, particularly in North America, which holds a substantial market share, while the Asia-Pacific region experiences rapid growth due to its vast population in need of care. Enhanced healthcare infrastructure investments further bolster market opportunities.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Prescription Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Prescription Drugs Market Segmental Analysis

Global Prescription Drugs Market is segmented by Product Type, Therapy Area, Route of Administration, End-Users, Distribution Channel and region. Based on Product Type, the market is segmented into Generics, Orphan and Other Prescription Drugs. Based on Therapy Area, the market is segmented into Oncology, Immunology, Ophthalmology, Respiratory, Dermatology, Gastroenterology, Urology, Gynaecology, Endocrinology and Others. Based on Route of Administration, the market is segmented into Oral, Topical, Parenteral and Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Prescription Drugs Market

The global prescription drugs market is being significantly driven by the increasing introduction of novel products, particularly generic versions of essential medications in developed countries like the United States. These generic options are gaining traction because they often offer comparable efficacy to brand-name drugs at a fraction of the cost, making them more accessible for patients. This affordability plays a crucial role, especially for individuals who cannot afford high-priced medications, as well as those in emerging markets facing financial constraints. Such trends underscore the potential for enhanced clinical outcomes and are projected to propel market growth throughout the forecast period.

Restraints in the Global Prescription Drugs Market

The global prescription drugs market is facing significant restraints that impede its growth, primarily due to the high costs associated with many medications. As essential health issues like cancer and cardiovascular diseases rise, particularly in developing regions such as Africa, Latin America, and Asia, the affordability of new products remains a critical barrier. These exorbitant prices, often ranging from USD 100,000 to USD 500,000, limit access to treatment for a substantial number of patients, many of whom encounter financial strain as they seek these essential drugs. Consequently, the lack of widespread adoption of effective medications poses a challenge for market expansion.

Market Trends of the Global Prescription Drugs Market

The Global Prescription Drugs market is witnessing a significant trend characterized by heightened R&D investments from leading pharmaceutical companies aimed at developing innovative drugs. This surge is largely driven by the rising prevalence of chronic diseases worldwide, leading to increased patient demand for effective treatments to address unmet clinical needs. As these chronic disorders often require aggressive treatment strategies, pharmaceutical firms are intensifying their efforts in clinical trials to bring new therapies to market. Additionally, there is a notable shift towards developing medications for rare diseases, which further propels market growth as companies aim to fulfill niche yet critical healthcare needs.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Technological Advancement
  • Regulatory Landscape
  • Case Studies

Global Prescription Drugs Market Size by Product Type & CAGR (2025-2032)

  • Market Overview
  • Generics
  • Orphan
  • Other Prescription Drugs

Global Prescription Drugs Market Size by Therapy Area & CAGR (2025-2032)

  • Market Overview
  • Oncology
  • Immunology
  • Ophthalmology
  • Respiratory
  • Dermatology
  • Gastroenterology
  • Urology
  • Gynaecology
  • Endocrinology
  • Others

Global Prescription Drugs Market Size by Route of Administration & CAGR (2025-2032)

  • Market Overview
  • Oral
  • Topical
  • Parenteral
  • Others

Global Prescription Drugs Market Size by End-Users & CAGR (2025-2032)

  • Market Overview
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Global Prescription Drugs Market Size by Distribution Channel & CAGR (2025-2032)

  • Market Overview
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Global Prescription Drugs Market Size & CAGR (2025-2032)

  • North America (Product Type, Therapy Area, Route of Administration, End-Users, Distribution Channel)
    • US
    • Canada
  • Europe (Product Type, Therapy Area, Route of Administration, End-Users, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Product Type, Therapy Area, Route of Administration, End-Users, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Product Type, Therapy Area, Route of Administration, End-Users, Distribution Channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Product Type, Therapy Area, Route of Administration, End-Users, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Pfizer Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Roche Holding AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb Company (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi S.A. (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca plc (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc (GSK) (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amgen Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novo Nordisk A/S (Denmark)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck KGaA (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biogen Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd. (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제